Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe
Authors:
- Laurence Torcel-PagnonLTLaurence Torcel-Pagnon
- Vincent BauchauVBVincent Bauchau
- Patrick MahyPMPatrick Mahy
- Myint Tin Tin HtarMHMyint Tin Tin Htar
- Marianne van der SandeMSMarianne van der Sande
- Cédric MahéCMCédric Mahé
- Tyra Grove KrauseTKTyra Grove Krause
- Anne CharratACAnne Charrat
- François SimondonFSFrançois Simondon
- Xavier KurzXKXavier Kurz
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Innovative Medicines Initiative (115557)
This publication has 6 references indexed in Scilit:
- Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccinesVaccine, 2020
- Impact of the Innovative Medicines Initiative on vaccine developmentNature Reviews Drug Discovery, 2018
- Advancing collaborative vaccine benefits and safety research in Europe via the ADVANCE code of conductVaccine, 2018
- The ADVANCE Code of Conduct for collaborative vaccine studiesVaccine, 2017
- The Innovative Medicines Initiative: an engine for regulatory scienceNature Reviews Drug Discovery, 2014
- Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilanceVaccine, 2011